Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ADMA Biologics's Enterprise Value is $2,086.2 Mil.
ADMA Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $107.6 Mil. Therefore, ADMA Biologics's EV-to-FCF for today is 19.40.
The historical rank and industry rank for ADMA Biologics's EV-to-FCF or its related term are showing as below:
ADMA'
s EV-to-FCF Range Over the Past 10 Years
Min: -48.32 Med: -2.9 Max: 414.14
Current: 19.4
During the past 13 years, the highest EV-to-FCF of ADMA Biologics was 414.14. The lowest was -48.32. And the median was -2.90.
ADMA's EV-to-FCF is ranked worse than 55.52% of 335
companies
in the Biotechnology industry
Industry Median: 15.51
vs ADMA: 19.40
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ADMA Biologics's PE Ratio (TTM) for today is calculated as:
ADMA Biologics's share price for today is $8.715.
ADMA Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.680.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ADMA Biologics EV-to-FCF Related Terms
ADMA Biologics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ADMA Biologics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's EV-to-FCF falls into.
ADMA Biologics's current Enterprise Value is $2,086.2 Mil.
ADMA Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $107.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a EV-to-FCF of 19.40 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ADMA Biologics and its competitors. According to the industry distribution chart, ADMA Biologics ranks #186 out of 335 companies in the Biotechnology industry, placing it in the top 55.5%.
Is ADMA Biologics' EV-to-FCF too high?
ADMA Biologics' current EV-to-FCF is 19.40. The Biotechnology industry median EV-to-FCF is 15.51. ADMA Biologics' value of 19.40 is 25.1% above this industry median. Based on the distribution chart, ADMA Biologics ranks #186 out of 335 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' EV-to-FCF compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #186 out of 335 companies for EV-to-FCF. This places ADMA Biologics in the lower half of its industry. The industry median EV-to-FCF is 15.51. ADMA Biologics' value of 19.40 is 25.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.51, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current EV-to-FCF of 19.40 is 25.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current EV-to-FCF is 19.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.11, compared to a current price of $8.72 — trading 51.9% below its estimated fair value. The current EV-to-FCF is 19.40 and 25.1% above the Biotechnology industry median of 15.51. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current EV-to-FCF is 19.40 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $8.72 is trading 51.9% below its estimated GF Value™ of $18.11.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
EV-to-FCF: 19.40
GF Value™: $18.11 vs. price of $8.72 (51.9% below fair value)
Industry Position: 25.1% above the Biotechnology median (#186 of 335)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
